Startups Leading Biopharmaceutical Innovation: Interview with Jennifer Good, Trevi Therapeutics

In this fascinating episode, we dive into what it takes to get a biotech startup off the ground with Jennifer Good, co-founder, President and CEO of Trevi Therapeutics - company dedicated to developing groundbreaking treatments for patients with chronic cough conditions.

Good discusses key lessons learned from building a biotech company and how Trevi lays the foundation for advancement in the treatment of other chronic cough conditions, plus: 

• 
  

  The initial spark or observation that led to the founding of Trevi Therapeutics.

  
  


• 
  

  A walk through the early days of Trevi and what challenges the startup faced in getting the company off the ground.

  
  


• Identifying nalbuphine ER (Haduvio) as a promising compound for chronic cough.


• The significant burden and impact of chronic cough on patients with Idiopathic Pulmonary Fibrosis (IPF).


• The findings and positive topline results from the Phase 2b CORAL trial. 
  

   

  
  


• The next steps for Haduvio following the trial and the implications for the future of chronic cough treatments.

Don't miss this highly informative episode which highlights groundbreaking advancements in the treatment of this debilitating condition.